Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 137-143

  Hasler Rapacz, Judith ^a   Kempen, Herman J ^b   Princen, Hans M G ^c   Kudchodkar, Bhalchandra J ^d   Lacko, Andras ^d   Rapacz, Jan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c TNO   (Netherlands)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

animal model; apolipoproteins; familial hypercholesterolemia; simvastatin; swine

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LATHOSTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCULATION; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SWINE;

EID: 0030053144     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.137     Document Type: Article

References (47)

1. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould LA, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I; efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
2. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schonten JA, Stalenhoef AFH. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolemia. Lancet. 1986;2:936-939.
3. Havel RJ, Hunninghake DB, Illingworth DR. Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE, Lees AM, Leon AS, Gardner K, Johnson G, Mellies MJ, Rhymer PA, Tun P. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholersterolemia: a multicenter study. Ann Intern. Med. 1987;107:609-615.
4. Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis. 1988;70:131-143.
5. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res. 1990;31:567-582.
6. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318: 81-86.
7. Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA. 1986;83:8370-8374.
8. Himber J, Missano B, Rudling U, Hennes M, Kempen HJ. Effect of stigmastanylphosphorylcholine (Ro 16-6532) and lovastatin on lipid and ipoprotein levels and lipoprotein metabolisms in the hamster on different diets. J Lipid Res. 1995;36:1567-1585.
9. Amin D, Gustafson S, Perrone MH. Lovastatin is hypertriglyceridemic in Syrian golden hamsters. Biochem Biophys Res Commun. 1988;157:530-534
10. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569-1582.
11. Kovanen FT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA. 1981;78:1194-1198.
12. Huff MW, Telford DE. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism. 1989;38:256-264.
13. Rapacz J, Hasler-Rapacz J. Investigations on the relationship between immunogenetic polymorphism of β-lipoproteins and the β-lipoprotein and cholesterol levels in swine. In: Lenzi S, Descovich GD, eds. Atherosclerosis and Cardiovascular Diseases. Bologna, Italy: Editrice Compositori; 1984:99-108.
14. Hasler-Rapacz J, Prescott MF, Von Linden-Reed J, Rapacz JM Jr, Hu Z, Rapacz J. Elevated concentrations of plasma lipids and apolipoproteins B, C-III, and E are associated with the progression of coronary artery disease in familial hypercholesterolemic swine. Arterioscler Thromb Vase Biol. 1995;15:583-592.
15. Rapacz J, Dentine MR, Hasler-Rapacz J, Rapacz JM Jr. A major familial hypercholesterolemia subphenotype in swine is inherited as an autosomal recessive trait and its gene is not linked to the apoB locus. Atherosclerosis. 1994;109;6. Abstract.
16. Brown MS, Goldstein JL. Familial hypercholesterolemia, a genetic defect of the low-density lipoprotein receptor. N Engl J Med. 1976; 294:1386-1390.
17. Prescott MF, McBride CH, Hasler-Rapacz J, Von Linden J, Rapacz J. Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia (IHLC) hearing mutant alleles for apolipoprotein B. Am J Pathol. 1991;139:139-147.
18. Prescott MF, Hasler-Rapacz J, Von Linden-Reed J, Rapacz J. Familial hypercholesterolemia associated with coronary atherosclerosis in swine bearing different alleles for apolipoprotein B. In: Numano F, Wissler RW, eds. Atherosclerosis III: Recent Advances in Atherosclerosis Research. New York, NY: Annals of the New York Academy of Science; 1995;748:283-293.
19. Hasler-Rapacz JO, Nichols TC, Griggs TR, Bellinger DA, Rapacz J. Familial and diet-induced hypercholesterolemia in swine: lipid, ApoB, and ApoA-I concentrations and distributions in plasma and lipoprotein subfractions. Arterioscler Thromb. 1994;14:923-930.
20. 1 homozygous and heterozygous swine with hypercholesterolemia. J Lipid Res. 1990;13:839-847.
21. Lowe SW, Checovich WJ, Rapacz J, Attic AD. Defective receptor binding of low density lipoproteins from pigs possessing mutant apolipoprotein B alleles. J Biol Chem. 1988;263:15467-15473.
22. Checovich WJ, Fitch WL, Krauss RM, Smith MP, Rapacz J, Smith CL, Attie AD. Defective catabolism and abnormal composition of low-density lipoproteins from mutant pigs with hypercholesterolemia. Biochemistry. 1988;27:1934-1941.
23. Aiello RJ, Nevin DN, Ebert DL, Uelmen PJ, Kaiser ME, MacCluer JW, Blangero J, Dyer TD, Attie AD. Apolipoprotein B and a second major gene locus contribute to phenotypic variation of spontaneous hypercholesterolemia in pigs. Arterioscler Thromb. 1994;14:409-419.
24. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
25. Kempen HJM, Glatz JFC, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29: 1149-1155.
26. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6: 24-27.
27. Mancini G, Carbonara AO, Heremans JF, Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochem. 1965;2:235-254.
28. Manabe M, Abe T, Nozawa M, Maki A, Hirata M, Itakura H. New substrate for determination of serum lecithin cholesterol:acyltransferase. J Lipid Res. 1987;28:1206-1215.
29. Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma: relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb. 1991;11:64-70.
30. Burstein M, Scholnick HR. Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-595.
31. Meijer GW, Van der Palen JGP, De Vries H, Kempen HJM, Van der Voort HA, Van Zutphen LFM, Beynen AC. Evaluation of the use of serum lathosterol concentration to assess whole-body cholesterol synthesis in rabbits. J Lipid Res. 1992;33:281-286.
32. Grundy SM, Vega GL. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res. 1985;26:1464-1475.
33. Mol MJTM, Erkelens DW, Gevers Leuven JA, Schouten JA, Stalenhoef AFH. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia. Atherosclerosis. 1988;69:131-137.
34. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of Simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol. 1993;71:1408-1414.
35. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering of 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
36. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blakenhorn DH. Effects of lovastatin on apoA- and apoB-containing lipoproteins: families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb. 1994;14:1906-1914.
37. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and Simvastatin in patients with primary type Ha or IIb hyperlipidemia. Arch Intern Med. 1994; 154;441-449.
38. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V. Mindell J, Mount J, Painter R, Parish S, Slavin B, Sleight P, Youngman L, Peto R. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994;15:255-269.
39. Singer II. Kawka DW, Kazazis DM, Alberts AW, Chen JS, Huff JW, Ness GC. Hydroxymethylglutaryl-coenzyme A reductase-con taining hepatocytes are distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci USA. 1984;81: 5556-5560.
40. Li AC, Tanaka RD, Callaway K, Fogelman AM, Edwards PA. Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA synthase in the rat liver and intestine is affected by cholestyramine and mevinolin. J Lipid Res. 1988;29:781-796.
41. 2 and platelet factor 4 in pigs with inherited hyperlipidemias. Am J Clin Nutr. 1991;53: 1042S-1046S.
42. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJK. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268:11230-11238.
43. Zhao S-P, Smelt AHM, Van den Maagdenberg AMJM, Van Tol A, Vroom TFFP, Gevers Leuven JA, Frants RR, Havekes LM, Van der Laarse A, Van 't Hooft FM. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158→Cys), E3-Leiden, and E2(Lys146→Gln), and effects of treatment with simvastatin. Arterioscler Thromb. 1994;14: 1705-1716.
44. Warden CH, Langner CA, Gordon JI, Taylor BA, McLean JW, Lusis AJ. Tissue specific expression, developmental regulation and chromosomal mapping of the lecithin: cholesterol acyltransferase gene. J Biol Chem. 1989;264:21573-21581.
45. Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass: its relationship to LCAT activity and cholesterol esterification rate. J. Lipid Res. 1981;22:1206-1213.
46. Franconc OL, Gurakar A, Fielding C. Distribution and functions of tecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. J Biol Chem. 1989;264:7066-7072.
47. Ha YC, Calvert GD, McIntosh GH, Barter PJ. A physiologic role of the esterified cholesterol transfer protein: in vivo studies in rabbits and pigs. Metabolism. 1981;30:380-383.